Department of Surgery, Ajou University School of Medicine, Suwon, Korea.
Department of Radiology, Ajou University School of Medicine, Suwon, Korea.
Surgery. 2021 Sep;170(3):743-747. doi: 10.1016/j.surg.2021.03.056. Epub 2021 May 2.
The management of papillary thyroid microcarcinomas with TERT ± BRAF V600E mutations remains controversial owing to their potential associations with tumor aggressiveness. This study evaluated the clinical implications of these mutations in management of patients with papillary thyroid microcarcinomas.
Between June 2019 and October 2020, surgical specimens from 504 consecutive patients with papillary thyroid microcarcinomas were obtained at a tertiary hospital. The mutation statuses of TERT promoter and BRAF V600E were assessed by polymerase chain reaction. The prevalence and relationships of TERT ± BRAF V600E mutations with clinical, radiological, and pathological characteristics were evaluated.
Of 504 patients with papillary thyroid microcarcinomas, TERT ± BRAF V600E mutations were found in 3.2% (16/504). Of these 16 patients, 93.8% (15/16) of papillary thyroid microcarcinomas with TERT promoter mutations also harbored BRAF V600E mutations. Correlation analysis showed that TERT ± BRAF V600E mutations were not associated with aggressive clinical, radiological, or pathological features (P > .05). The presence of lymph node metastasis was not associated with mutation status (P = .834).
TERT ± BRAF V600E mutations in patients with papillary thyroid microcarcinomas are not associated with any unfavorable clinicopathological features, including lymph node metastasis status.
TERT ± BRAF V600E 突变的甲状腺微小乳头状癌的治疗管理仍存在争议，因为它们可能与肿瘤侵袭性有关。本研究评估了这些突变在甲状腺微小乳头状癌患者管理中的临床意义。
在 2019 年 6 月至 2020 年 10 月期间，在一家三级医院获得了 504 例连续的甲状腺微小乳头状癌患者的手术标本。通过聚合酶链反应评估 TERT 启动子和 BRAF V600E 的突变状态。评估了 TERT ± BRAF V600E 突变与临床、影像学和病理特征的相关性和关系。
在 504 例甲状腺微小乳头状癌患者中，发现 TERT ± BRAF V600E 突变占 3.2%（16/504）。在这 16 例患者中，TERT 启动子突变的甲状腺微小乳头状癌中 93.8%（15/16）也存在 BRAF V600E 突变。相关性分析表明，TERT ± BRAF V600E 突变与侵袭性临床、影像学或病理特征无关（P >.05）。淋巴结转移的存在与突变状态无关（P =.834）。
甲状腺微小乳头状癌患者 TERT ± BRAF V600E 突变与任何不良临床病理特征无关，包括淋巴结转移状态。
